Abivax Rebounds as Phase 3 Safety Data Eases Investor Fears Over Obefazimod

Updated ABTECT trial results alleviate adverse-event concerns for the once-daily UC drug, offering a potential safety edge over JAK inhibitors in a crowded inflammatory bowel disease market.

ndtv-profit-business · 6/30/2026, 6:18:47 PM · Ask about this →